Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

NCT00400894 is registered in ClinicalTrials.gov with ProteoSys AG as lead sponsor.

NCT NCT00400894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00400894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Lead sponsor
ProteoSys AG
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2005
Completion date
September 30, 2006
Enrollment
750
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, prostate cancer, prostatic intraepithelial neoplasia